The abundance of V-ATPase, a heteromultimeric proton pump, on the plasma membrane of tumor cells correlates with their grade of invasiveness, suggesting its involvement in tumor metastasis. V-ATPase is hypothesized to create a proton efflux leading to an acidic pericellular microenvironment that promotes the activity of pro-invasive proteases. An 3
INTRODUCTION
Cancer is a major cause of mortality, which is primarily due to tumor metastasis . The vacuolar (V)-ATPase is emerging as a prominent player in the invasiveness of cancer cells .
Consistently, pharmacological inhibition of V-ATPase has been proposed as a strategy to oppose metastatic processes .
V-ATPases are heteromultimeric ATP-dependent proton pumps in eukaryotic cells (6) . These pumps are ubiquitously expressed and are thought to regulate the pH in Cell migration is the result of a complex interplay of various signaling machineries that must decode and transduce biochemically and physically diverse microenvironmental cues to enable a cell to adopt the most effective migratory strategy. Among these signaling axes, those emanating from growth factor receptors, such as EGFR, are important for directed migration, while Rho-GTPases, a subgroup of the Ras superfamily of GTPases, regulate cell morphology and actin cytoskeleton, and are therefore indispensable for controlling the machinery of cell migration .
Here, we report that the V-ATPase inhibitor archazolid hinders the migration of invasive cancer cells in vitro and in vivo. This is achieved by interfering with the endocytic traffic of Rac1 and EGFR. We suggest that V-ATPase contributes to spatially restricted activation of migratory transducers, which is required for the acquisition of polarized and directed tumor cell migration. Thus, this work provides novel insights on the efficacy and molecular mode of action of V-ATPase inhibitors, which could be of relevance for the development of therapeutic strategies against tumor invasiveness.
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MATERIAL AND METHODS
Compounds and antibodies
Archazolid A (Fig. S1A ) was purified and isolated as described previously (9) . Archazolid B (Fig. S1A ) was synthesized chemically as described . Both compounds were dissolved in dimethyl sulfoxide (DMSO) in high concentrated stocks and show similar bioactivity (Fig.   S1B ). Further dilutions were done in culture media or PBS. propidiumiodide was purchased from Sigma (Taufkirchen, Germany).
The following antibodies were used: Ductin-antibody (ATP6L, Millipore, Eschborn, Germany), actin, cortactin and Rab5A (Santa Cruz, Santa Cruz, USA), anti-pAkt/Akt, pEGFR/EGFR (cell signaling technologies, Danver, MA, USA), EGF-R for confocal microscopy (Santa Cruz), anti-Rac1 (Millipore, Eschborn, Germany). The following secondary antibodies were used:
goat-anti rabbit-488, goat-anti mouse-488 (AlexaFluor®, Life technologies, Darmstadt, Germany), goat-anti rabbit (Dianova, Hamburg, Germany), goat-anti mouse IgG2b (Biozol, Eching, Germany). Phalloidin-rhodamine was purchased from Sigma (Taufkirchen, Germany).
Cell culture
The human breast cancer cell line SKBR3 was kindly provided in 2009 by Dr. B. Mayer (Department of Surgery, Clinic Grosshadern, University of Munich, Germany). The cells were routinely tested every 6 month for their ER, PgR Her2, EGFR as well as Bcl-2 and Bcl-xL status. Hela cells were from ATCC and routinely tested for Mycoplasma contamination with MycoAlert™ Mycoplasma Detection Kit (LONZA, Basel, Switzerland) and cell crosscontamination with StemElite™ ID System (Promega, Mannheim, Germany). SKBR3 were maintained in McCoy's (PAA, Coelbe, Germany) medium supplemented with 10 % heatinactivated fetal calf serum (FCS, Biochrom AG, Berlin, Germany) and 1% Glutamine. Hela 6 cells were grown in DMEM medium (PAA, Coelbe, Germany) supplemented with 10 % South American serum (EuroClone, Milan, Italy) and 1 % L-Glutamine (EuroClone, Milan, Italy).
4T1-Luc cells were recently (< 6 month) purchased from Caliper (Alamenda, CA, USA) and cultivated in RPMI (PAA, Coelbe, Germany) with 10% FCS (Biochrom AG, Berlin, Germany).
All cells were routinely tested for mycoplasma contamination (LONZA, Basel, Switzerland).
Immunocytochemistry
SKBR3 cells were seeded on IBIDI-µ-slides (Martinsried, Germany) To stop assays cells were washed with PBS and fixed with 4% formaldehyde for 15 min, RT. Cells were permeabilized with 0.2% Triton X-100/PBS. Antibodies were diluted in 1% BSA/PBS containing 0.1% Triton. Samples were prepared for confocal microscopy (LSM 510 Meta; Zeiss, Oberkochen, Germany) by adding mounting media and coverslips on top of each sample. To monitor the uptake of EGF-rhodamine (Invitrogen, Karlsruhe, Germany) Archazolid B treated as well as control cells were starved for 2 h and incubated for 5 to 15 min with either EGF-rhodamine (Invitrogen, Karlsruhe, Germany) and analyzed by confocal microscopy.
Rac1 activation assay
After stimulation of cells with archazolid B for 24 h in DMEM media (PAA Laboratories, Coelbe, Germany), activation of Rac1 was induced by adding epidermal growth factor (EGF 100ng/ml) for 2 min. Cells were harvested and a Rac1 pulldown assay was performed following the manufacturer's instructions (Thermo Fisher Scientific, Bonn, Germany). Finally, active Rac1 was detected by western blot analysis.
Western blot
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes using tank blotting. For the detection of protein levels the ECL TM detection system (Amershan Pharmacia Biotech, Little Chalfont, UK) or the Odyssey Infrared Imaging system version 2.1 (LI-COR Biosciences, Lincoln, NE, USA) was used.
Quantitative real-time PCR
For quantitative real-time PCR the ABI 7300 RealTime PCR system with the TaqMan Universal PCR Mastermix (Life Technologies Corporation, Carlsbad, CA, USA) was used.
Probe and primers for the V-ATPase subunit c (ATP6L) were supplied as mix (Life Technologies Corporation, Carlsbad, CA, USA). GAPDH (probe and primers were from biomers, Ulm, Germany) was employed as housekeeping gene. Fluorescence increase was analyzed using the ABI 7300 system software. Calculation of relative mRNA was done according to Pfaffl.
Measurement of apoptotic cell death
Quantification of apoptotic cell death was performed as described by Nicoletti et 
Boyden chamber assay
Cells were seeded and treated with archazolid B at a confluence of 70% for 24/16h. 1x10 
Statistical analysis
All experiments were performed at least three times in duplicates/triplicates. Results are expressed as mean value ±SEM. One-way ANOVA/Dunnett or individual students t-tests were performed using GraphPadPrism TM . P-values < 0.05 were considered as significant.
RESULTS
Archazolid inhibits cell migration
Treatment with archazolid ( Fig. S1A ) at low nanomolar concentration inhibits migration of the breast cancer cell lines SKBR3 and MDA-MB 231 as well of the pancreatic cancer cell line L3.6pl using either Boyden chamber (Fig. 1A, Fig. S2A ) or wound healing-type of assays (Fig. S2B) . Importantly, archazolid, at all the concentrations and timepoints tested, had no effects on cell survival ruling out indirect apoptotic effects as a cause of reduced cell migration (Fig. 1A , S2A lower right panel). Next, we tested the influence of archazolid on cell migration in a chemotactic assay. To this end, SKBR3 cells were exposed to a diffusive gradient of fetal calf serum (FCS) ranging from 0 to 10%. As shown in Fig. 1B , non-treated, control cells moved chemotactically toward the highest FCS concentration. Conversely, pretreatment with archazolid significantly impaired chemotaxis by reducing directional migration (expressed as y-forward migration index). A slight alteration in the cumulative distance and in velocity of cell movement was observed suggesting that directed migration rather than cell mobility is mainly affected by archazolid.
Archazolid affects EGF-R cellular distribution and cell polarization
Growth factor receptors, including the epidermal growth factor receptor (EGF-R), play a crucial role in directed cell migration as confirmed by using a EGF-R inhibitor (Fig. S4) .
Whereas the amounts of EGF-R protein on the cell surface increased upon archazolid treatment (24h) ( Fig. 2A left panel, Fig. S3 ), the total amount of EGF-R was unchanged ( Fig.   2A , right panel) and was still able to be activated as indicated by phosphorylation at Tyr 1068, although the extent and kinetic of activation were slightly decreased ( Fig. 2A, lower panel). Conversely, we observed dramatic changes of EGF-R surface distribution after archazolid treatment by confocal microscopy analysis of not-permeabilized cells. In control cells, EGF-R localizes and is enriched at the leading edge of migrating cells. In archazolid-treated cells, in contrast, EGF-R was distributed all over the cell surface and failed to accumulate along the leading edge extending in the direction of migration. This altered cellular distribution of EGF-R likely reflects archazolid inhibition of lamellipodia extension as revealed by anti-actin staining (Fig. 2B, lower panel) . Furthermore the localization of the microtubule organizing center (MTOC) was affected by archazolid treatment. Whereas in control cells the MTOC is localized at the very front of the nucleus in the direction of migration, the MTOC of archazolid treated cells was randomly positioned with respect to the nucleus and the front of migration (Fig. 2C) . Thus, archazolid inhibits cell polarization.
To explore the mechanisms of archazolid action, we initially tested whether this inhibitor affects EGF-R internalization and trafficking, which may in turn control EGFR signaling to actin remodeling. EGF-R is rapidly internalized upon ligand binding. However, in archazolid treated cells internalization of EGF-R was significantly delayed (Fig. 2D) . Notably also the kinetic of activation of Akt in response to EGF was altered by archazolid treatment, which caused a delay in maximal activation and a significant reduction in the duration of Akt signaling (Fig. 2E, upper panel) . Likewise for EGF-R, the polarized distribution of activated Akt in migrating cells was significantly impaired, further corroborating the ability of archazolid treatment to inhibit polarized lamellipodia extension. (Fig. 2E, lower panel) .
Archazolid inhibits cell spreading and ruffle formation by preventing Rac1 activation
Cells that attach and spread on ECM substrates are known to activate signaling pathways and undergo morphological changes in their shape and remodelling of the actin cytoskeleton that recapitulate events typical of migratory cells . Thus, we tested the effect of archazolid on cell spreading onto fibronectin (FN) coated plates. Archazolid treatment did not significantly altered the number of adhered cells, suggesting that adhesion receptors responsible for FN interaction are functional (Fig. 3A left panel) . Conversely, archazolid-treated, freshly adherent SKBR3 cells underwent prominent morphological changes that were monitored in real time both by changes in impedance, which is directly proportional to the area of cells in contact with the substrate (xCelligence, Roche, Fig. 3A, right panel) and by determination of ruffle formation (Fig. 3B, left panel) . In contrast to control, archazolid-treated cells were significantly less efficient in spreading and failed to form prominent actin rich peripheral lamellipodia and ruffles.
Lamellipodia extension and ruffle formation are primarily controlled by the Rho GTPase Rac1, which localizes to leading edges to promote these migratory structures. Thus, we tested whether archazolid may affect either the localization or activation (or both) of Rac1. Confocal analysis of freshly adherent control cells showed a distinct localization of Rac1, which, as expected, accumulated at the cell periphery where actin-rich lamellipodial sheets are localized. Archazolid completely abrogated the distribution of Rac1 to the plasma membrane most likely because the peripheral enrichment of filamentous actin (ruffels) also disappears upon archazolid treatment (Fig. 3B, right panel) . A similar picture was observed in migrating cells in a scratch assay. Under these conditions, archazolid inhibited the formation of wound-directed, Rac1-, cortactin-, and F-actin-positive polarized lamellipodia (Fig. 3D ). All these morphological phenotypes can be easily accounted by a direct inhibitory effect of archazolid on Rac1 activation. Consistent with this hypothesis, EGF-induced Rac-GTP levels were significantly reduced by archazolid treatment (Fig. 3C) , suggesting that pathways leading to the activation of this GTPase are a primary target of archazolid action. This is further supported by overexpression of either wild type Rac1 (Rac-WT) or constitutive active Rac1 (RacQL), which could both rescue the inhibition of migration caused by Archazolid (Fig. 3E) .
Downregulation of V-ATPase subunit c inhibits migration and Rac1 activation
Archazolid binds to the V-ATPase subunit c. To unequivocally establish that the effects of archazolid are due to the inhibition of V-ATPase subunit c, we genetically silenced the V0 13 subunit c (ATP6L) using siRNA. Downregulation of ATP6L impaired both cell migration and polarized lamellipodia and ruffle formation observed in a scratch wound healing assay (Fig. 4 A/B). This effect is not cell type specific, since pancreatic cancer cells L3.6pl were equally inhibited by silencing of ATP6L (Fig. S5) . Notably and similar to archazolid, silencing of ATP6L inhibited both the activation of Rac1 (Fig. 4C) and its accumulation at the leading edge of migrating SKBR3 cells due to loss of ruffles (Fig. 4B, right panel) . These results support the hypothesis that the V-ATPase subunit c plays a crucial role during the migration process by critically participating in the activation of Rac1.
V-ATPase-inhibition affects Rab5-induced Rac1 activation
Recently, the recycling molecule Rab5 has been reported to play an important role in the activation of the Rac1-mediated actin remodeling and cell migration . In keeping with these observations, we show that Rab5 is sufficient to induce the formation of Rac1-dependent actin-rich migratory structures, including circular dorsal ruffles and peripheral ruffles (Fig.   5A ). Thus we tested whether archazolid interfered also with Rab5-evoked morphological changes. Both, peripheral and circular dorsal ruffle formation was significantly reduced in Rab5-expressing Hela cells after 24h of archazolid treatment (Fig. 5A) . Similarly, Rab5-mediated activation of Rac1 (Fig. 5B, left panel) was significantly inhibited by archazolid treatment (Fig. 5B, right panel) .
In Rab5-expressing, untreated cells, Rac1 can, as previously reported , localize to enlarged early endosomes [revealed by the presence of the early endosome antigen-1 (EEA1)] (Fig. 5C, left panel) . Treatment with archazolid, however, prevented the accumulation of Rac1 on Rab5 vesicles, as revealed both by directly monitoring Rac1 cellular distribution (Fig. S6) or using a Rac1 biosensor (PAK CRIB) that specifically binds to activated Rac1 (Fig. 5C, right panel) .
Archazolid inhibits metastasis in vivo
To extend the relevance of the inhibitory effects of archazolid on chemotactic migration and cell invasion, we next tested whether this drug was effective in impairing cancer dissemination in xenograft mouse models. To this end we employed the 4T1-Luc syngeneic metastatic mouse breast cancer model . This model is based on the 4T1-Luc mouse mammary tumor cell line, which when injected intravenously disseminates to distant organs, homing to lungs, liver, bone and brain over a short period of time. These cells are engineered to express a luciferase reporter to enable real time monitoring of developing tumor by live imaging. Under these conditions, mock treated, 4T1-injected animals formed easily detectable lung metastases, which were drastically inhibited by intravenous injection of archazolid, which at the concentrations tested (1mg/kg i.v.) did not cause any obvious signs of toxicity (Fig. 5A and Fig. S7A-B) . ,
DISCUSSION
The study presented here gives evidence for a role of V-ATPase in tumor metastasis and further reveals the molecular mechanisms of its action (Fig. S8) Notably, a general influence of V-ATPase inhibition on internalization as well as recycling processes has been reported before . We confirmed this finding also for archazolid, which inhibits uptake of dextran, but not of transferrin after short time of treatment (Fig. S10A) .
While it abrogates transferrin/transferrin-R uptake after prolonged exposure (Fig. S10B) .
With respect to mechanisms underlying V-ATPase action on internalization/recycling, it is important to note that endosomes and lysosomes, where recycling and degradation takes place, are acidified by V-ATPases . The acidic pH is important for the dissociation of ligands from its receptors and degradation or recycling processes . Increase of pH induced by bafilomycin, for example, has been shown to affect the delivery of endocytosed molecules to late endosomes or lysosomes in some, but not all cell lines tested . We analyzed SKBR3 cells by transmission-electron-microscopy ( Fig. S10C) and found considerably more multivesicular-bodies (MVBs) in cells after archazolid treatment as compared to control cells.
MVBs are degradative endosomal organelles, mediating trafficking between early and late endosomes . MVBs were strongly enlarged after archazolid treatment (Fig. S10C) .
Interestingly, this phenomenon was also described in a study focusing on the involvement of V-ATPase activity in Notch-Signaling . Since an even more acidic pH is necessary for lysosomal degradation process, V-ATPase inhibition by archazolid might inhibit the final fusion with lysosomes, halting the degradative, and probably also recycling routes, leading to enlargement of MVBs. Likely these "high pH" MVB are inefficient degradative factory that may trap cargos and endosomal associated molecules that would otherwise be routed to recycling pathways for subsequent round of signaling. Ultimately, this may result in reduced or altered delivery of internalized molecules, such as in the case of EGFR, to the proper location on the plasma membrane preventing proper and sustained EGFR activation. Similar alteration in trafficking of endosomal membrane associated molecules recycling back to the plasma membrane may also occur for impaired activation of Rac1, which after archazolid treatment, is no longer able to enter the Rab5-mediated endosomal routes for subsequent delivery back to the plasma membrane. How changes in endosomal pH affect Rac1 recruitment to these organelles is unclear at this stage. One possibility is that local changes of the pH at the plasma membrane, where Rac1 or its GEFs are primarily localized and activated, are required for Rac1 (or its activators) to subsequently enter endocytic organelles.
Indeed similar reduction of Rac1 in endosomes could be observed after interference with clathrin (20) suggesting that plasma membrane localized Rac may follow a canonical endocytic routes that may require local changes of pH to be effective. Whether this is indeed the case remains, however, to be tested in future investigations.
Whatever the case, Impaired endocytic traffic induced by V-ATPase is hypothesized to affect the spatially restricted activation of Rac1, a central regulator of actin remodeling and cell migration . Consistently, archazolid treatment or silencing the V0 subunit c of the VATPase, the binding site of archazolid, abrogate Rac1-dependent F-actin remodeling, Factin-mediated formation of ruffles or lamellipodia as well as the recruitment of active Rac1 to these migratory structures. These results also demonstrate that archazolid exerts its effect by specifically targeting V-ATPase, or more precisely of the V0 subunit c, further supporting its role in tumor cell migration similarly to what reported for to the subunit a of V-ATPase .
Spatial restriction of Rac1 signaling has been shown to depend on Rab5 endo/exocitic cycles . Rab5, in addition to be a master regulator of endocytosis by controlling the biogenesis and fate of early endosomes, was also shown to be sufficient to promote, through Rac1, the formation of a diverse set of migratory protrusions, including lamellipodia and circular dorsal ruffles . Notably, archazolid robustly inhibits all these structures. These effects are accompanied by loss of Rac1 from endosomal membrane, which results in reduced delivery of this GTPase to cell protrusion, and impaired directional migration. Thus, archazolid appears to interfere both with endocytic trafficking of Rac1 as well as EGFR. Whether EGFR needs to be internalized and recycled to trigger Rac1 internalization and activation or the two events are occurring at the same time independently of each other remains to be addressed in future work. 
